U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H28O2
Molecular Weight 324.4565
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETONOGESTREL

SMILES

CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C

InChI

InChIKey=GCKFUYQCUCGESZ-BPIQYHPVSA-N
InChI=1S/C22H28O2/c1-4-21-13-14(3)20-17-9-7-16(23)12-15(17)6-8-18(20)19(21)10-11-22(21,24)5-2/h2,12,17-20,24H,3-4,6-11,13H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1

HIDE SMILES / InChI

Molecular Formula C22H28O2
Molecular Weight 324.4565
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021529s004lbl.pdf

Etonogestrel, also known as 11-methylenelevonorgestrel and 3-keto-desogestrel, is a steroidal progestin used in hormonal contraceptives, most notably the subdermal implants Nexplanon and Implanon and the vaginal ring NuvaRing. Etonogestrel is a progestin or a synthetic form of the naturally occurring female sex hormone, progesterone. In a woman's normal menstrual cycle, an egg matures and is released from the ovaries (ovulation). The ovary then produces progesterone, preventing the release of further eggs and priming the lining of the womb for a possible pregnancy. If pregnancy occurs, progesterone levels in the body remain high, maintaining the womb lining. If pregnancy does not occur, progesterone levels in the body fall, resulting in a menstrual period. Etonogestrel tricks the body processes into thinking that ovulation has already occurred, by maintaining high levels of the synthetic progesterone. This prevents the release of eggs from the ovaries. Etonogestrel binds to the progesterone and estrogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like etonogestrel will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
IMPLANON

Approved Use

IMPLANON™ (etonogestrel implant) is indicated for women for the prevention of pregnancy.

Launch Date

2006
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.59 ng/mL
75 μg 1 times / day multiple, oral
dose: 75 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ETONOGESTREL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6.097 ng × h/mL
75 μg 1 times / day multiple, oral
dose: 75 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ETONOGESTREL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
29.2 h
75 μg 1 times / day multiple, oral
dose: 75 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ETONOGESTREL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2%
ETONOGESTREL blood
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: F
Sources:
Disc. AE: Menstrual irregularity, Emotional lability...
AEs leading to
discontinuation/dose reduction:
Menstrual irregularity (11.1%)
Emotional lability (2.3%)
Weight increase (2.3%)
Headache (1.6%)
Acne (1.3%)
Depression (1%)
Sources:
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: F
Sources:
Other AEs: Headache, Vaginitis...
Other AEs:
Headache (24.9%)
Vaginitis (14.5%)
Weight increase (13.7%)
Acne (13.5%)
Breast pain (12.8%)
Abdominal pain (10.9%)
Pharyngitis (10.5%)
Leukorrhea (9.6%)
Influenza-like symptoms (7.6%)
Dizziness (7.2%)
Dysmenorrhea (7.2%)
Back pain (6.8%)
Emotional lability (6.5%)
Nausea (6.4%)
Pain (5.6%)
Nervousness (5.6%)
Depression (5.5%)
Hypersensitivity (5.4%)
Injection site pain (5.2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Depression 1%
Disc. AE
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: F
Sources:
Acne 1.3%
Disc. AE
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: F
Sources:
Headache 1.6%
Disc. AE
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: F
Sources:
Menstrual irregularity 11.1%
Disc. AE
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: F
Sources:
Emotional lability 2.3%
Disc. AE
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: F
Sources:
Weight increase 2.3%
Disc. AE
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: F
Sources:
Pharyngitis 10.5%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: F
Sources:
Abdominal pain 10.9%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: F
Sources:
Breast pain 12.8%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: F
Sources:
Acne 13.5%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: F
Sources:
Weight increase 13.7%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: F
Sources:
Vaginitis 14.5%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: F
Sources:
Headache 24.9%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: F
Sources:
Injection site pain 5.2%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: F
Sources:
Hypersensitivity 5.4%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: F
Sources:
Depression 5.5%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: F
Sources:
Nervousness 5.6%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: F
Sources:
Pain 5.6%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: F
Sources:
Nausea 6.4%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: F
Sources:
Emotional lability 6.5%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: F
Sources:
Back pain 6.8%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: F
Sources:
Dizziness 7.2%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: F
Sources:
Dysmenorrhea 7.2%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: F
Sources:
Influenza-like symptoms 7.6%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: F
Sources:
Leukorrhea 9.6%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: F
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
yes
yes (co-administration study)
Comment: Coadministration of Efavirenz (CYP3A4 inducer) decreased Etonogestrel plasma concentration one week after implant insertion by 84%.
Page: 5, 15, (ClinPharm) 14, 25
PubMed

PubMed

TitleDatePubMed
A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon.
2006-01
Failure of Implanon contraception in a patient taking carbamazepin for epilepsia.
2006-01
A multicentre study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive.
2006-01
Effect on insulin sensitivity of Implanon vs. GnRH agonist in women with endometriosis.
2005-12
Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells.
2005-12
How to remove impalpable Implanon implants.
2005-10
An assessment of the first 3 years' use of Implanon in Luton.
2005-10
[Ectopic pregnancy with etonogestrel contraceptive implant (Implanon): first case].
2005-10
[Hormonal contraception for males--an option for adolescents?].
2005-10
Transitory reduction of platelet aggregation with the use of etonogestrel implant in healthy women.
2005-09
Clinical experience and acceptability of the etonogestrel subdermal contraceptive implant.
2005-09
Australian women's experience with Implanon.
2005-08
Self removal of Implanon: a case report.
2005-07
FFPRHC Guidance (July 2005): The use of contraception outside the terms of the product licence.
2005-07
The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel.
2005-07
Gateways to clinical trials.
2005-06
[Preliminary results from the OPNI observatory: long-term follow-up of a cohort of women using the progestagen contraceptive implant Implanon].
2005-05
Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel.
2005-05
Contraceptive implants.
2005-04
Clinical challenge with Implanon removal: a case report.
2005-04
Unintended pregnancies with the etonogestrel implant (Implanon): a case series from postmarketing experience in Australia.
2005-04
Effect of Implanon on insulin resistance in women with Polycystic Ovary Syndrome.
2005-04
Ultrasound localisation of non-palpable Implanon.
2005-04
A multicenter phase IIb study of a novel combination of intramuscular androgen (testosterone decanoate) and oral progestogen (etonogestrel) for male hormonal contraception.
2005-04
Effects of two types of hormonal contraception--oral versus intravaginal--on the sexual life of women and their partners.
2005-04
One year study of Implanon on the adverse events and discontinuation.
2005-03
Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial.
2005-03
Migration of implanon: two case reports.
2005-01
Treatment of pelvic endometriosis with etonogestrel subdermal implant (Implanon).
2005-01
Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials.
2005
Acceptability and side-effects of Implanon in Switzerland: a retrospective study by the Implanon Swiss Study Group.
2004-12
Implanon studies conducted in Indonesia.
2004-11
Effect of etonogestrel subdermal contraceptive implant (Implanon) on liver function tests -- a randomized comparative study with Norplant implants.
2004-11
Depot testosterone with etonogestrel implants result in induction of azoospermia in all men for long-term contraception.
2004-11
[Two patients with a non-palpable, subcutaneously implanted contraceptive].
2004-09-04
[The progestagen-containing implant (Implanon); who is responsible for what?].
2004-09-04
A comparative study on the effects of a contraceptive vaginal ring NuvaRing and an oral contraceptive on carbohydrate metabolism and adrenal and thyroid function.
2004-09
[Acceptability of the etonogestrel-containing contraceptive implant (Implanon)].
2004-09
Implanon and medical indemnity: a case study of risk management using the Australian standard.
2004-07-19
Implanon use in Thai women above the age of 35 years.
2004-06
The combined contraceptive vaginal ring (NuvaRing) and lipid metabolism: a comparative study.
2004-05
Pharmacological profile of progestins.
2004-04-15
New delivery systems in contraception: vaginal rings.
2004-04
Implanon audit.
2004-04
Treatment of endometriotic catamenial haemoptysis with etonogestrel subdermal implant.
2004-04
Experience with Implanon in a northeast London family planning clinic.
2004-03
The combined contraceptive vaginal ring, NuvaRing, and tampon co-usage.
2004-03
The contraceptive vaginal ring, NuvaRing, and antimycotic co-medication.
2004-02
Relative cost effectiveness of Depo-Provera, Implanon, and Mirena in reversible long-term hormonal contraception in the UK.
2004
Vaginal rings for menopausal symptom relief.
2004
Patents

Sample Use Guides

Usual Adult Dose for Contraception One 68 mg implant inserted subdermally. The implant should not be left in place more than three years.
Route of Administration: Transdermal
Etonogestrel (1716 pg/mL) significantly altered antiretroviral uptake across THP-1, BC-3 (CD8+) cell lines, incubated for one hour with tenofovir and emtricitabine to assess uptake except
Substance Class Chemical
Created
by admin
on Wed Apr 02 09:43:28 GMT 2025
Edited
by admin
on Wed Apr 02 09:43:28 GMT 2025
Record UNII
304GTH6RNH
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ETONOGESTREL
INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
DESOGESTREL IMPURITY D
EP  
Preferred Name English
ETONOGESTREL [MI]
Common Name English
ORG 3236
Code English
etonogestrel [INN]
Common Name English
13-Ethyl-17-hydroxy-11-methylene-18,19-dinor-17?-pregn-4-en-20-yn-3-one
Common Name English
ETONOGESTREL [ORANGE BOOK]
Common Name English
DESOGESTREL IMPURITY D [EP IMPURITY]
Common Name English
ETONOGESTREL [USAN]
Common Name English
NUVARING COMPONENT ETONOGESTREL
Common Name English
IMPLANON
Brand Name English
ORG-3236
Code English
ETONOGESTREL [MART.]
Common Name English
ETONOGESTREL [VANDF]
Common Name English
DESOGESTREL RELATED COMPOUND C [USP-RS]
Common Name English
ETONOGESTREL [USP-RS]
Common Name English
13-Ethyl-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-17-ol-3-one
Systematic Name English
18,19-DINOR-17.ALPHA.-PREGN-4-EN-20-YN-3-ONE, 13-ETHYL-17-HYDROXY-11-METHYLENE-
Common Name English
DESOGESTREL RELATED COMPOUND C
USP-RS  
Common Name English
Etonogestrel [WHO-DD]
Common Name English
Classification Tree Code System Code
NDF-RT N0000011301
Created by admin on Wed Apr 02 09:43:28 GMT 2025 , Edited by admin on Wed Apr 02 09:43:28 GMT 2025
WHO-ATC G03AC08
Created by admin on Wed Apr 02 09:43:28 GMT 2025 , Edited by admin on Wed Apr 02 09:43:28 GMT 2025
NCI_THESAURUS C776
Created by admin on Wed Apr 02 09:43:28 GMT 2025 , Edited by admin on Wed Apr 02 09:43:28 GMT 2025
WHO-VATC QG03AC08
Created by admin on Wed Apr 02 09:43:28 GMT 2025 , Edited by admin on Wed Apr 02 09:43:28 GMT 2025
LIVERTOX 388
Created by admin on Wed Apr 02 09:43:28 GMT 2025 , Edited by admin on Wed Apr 02 09:43:28 GMT 2025
NDF-RT N0000175602
Created by admin on Wed Apr 02 09:43:28 GMT 2025 , Edited by admin on Wed Apr 02 09:43:28 GMT 2025
Code System Code Type Description
RS_ITEM_NUM
1268783
Created by admin on Wed Apr 02 09:43:28 GMT 2025 , Edited by admin on Wed Apr 02 09:43:28 GMT 2025
PRIMARY
ChEMBL
CHEMBL1531
Created by admin on Wed Apr 02 09:43:28 GMT 2025 , Edited by admin on Wed Apr 02 09:43:28 GMT 2025
PRIMARY
DRUG CENTRAL
1110
Created by admin on Wed Apr 02 09:43:28 GMT 2025 , Edited by admin on Wed Apr 02 09:43:28 GMT 2025
PRIMARY
CHEBI
50777
Created by admin on Wed Apr 02 09:43:28 GMT 2025 , Edited by admin on Wed Apr 02 09:43:28 GMT 2025
PRIMARY
DAILYMED
304GTH6RNH
Created by admin on Wed Apr 02 09:43:28 GMT 2025 , Edited by admin on Wed Apr 02 09:43:28 GMT 2025
PRIMARY
RXCUI
14584
Created by admin on Wed Apr 02 09:43:28 GMT 2025 , Edited by admin on Wed Apr 02 09:43:28 GMT 2025
PRIMARY RxNorm
IUPHAR
7590
Created by admin on Wed Apr 02 09:43:28 GMT 2025 , Edited by admin on Wed Apr 02 09:43:28 GMT 2025
PRIMARY
LACTMED
Etonogestrel
Created by admin on Wed Apr 02 09:43:28 GMT 2025 , Edited by admin on Wed Apr 02 09:43:28 GMT 2025
PRIMARY
NCI_THESAURUS
C47528
Created by admin on Wed Apr 02 09:43:28 GMT 2025 , Edited by admin on Wed Apr 02 09:43:28 GMT 2025
PRIMARY
RS_ITEM_NUM
1173268
Created by admin on Wed Apr 02 09:43:28 GMT 2025 , Edited by admin on Wed Apr 02 09:43:28 GMT 2025
ALTERNATIVE
ECHA (EC/EINECS)
258-936-2
Created by admin on Wed Apr 02 09:43:28 GMT 2025 , Edited by admin on Wed Apr 02 09:43:28 GMT 2025
PRIMARY
INN
6832
Created by admin on Wed Apr 02 09:43:28 GMT 2025 , Edited by admin on Wed Apr 02 09:43:28 GMT 2025
PRIMARY
MERCK INDEX
m5198
Created by admin on Wed Apr 02 09:43:28 GMT 2025 , Edited by admin on Wed Apr 02 09:43:28 GMT 2025
PRIMARY Merck Index
EVMPD
SUB07335MIG
Created by admin on Wed Apr 02 09:43:28 GMT 2025 , Edited by admin on Wed Apr 02 09:43:28 GMT 2025
PRIMARY
FDA UNII
304GTH6RNH
Created by admin on Wed Apr 02 09:43:28 GMT 2025 , Edited by admin on Wed Apr 02 09:43:28 GMT 2025
PRIMARY
DRUG BANK
DB00294
Created by admin on Wed Apr 02 09:43:28 GMT 2025 , Edited by admin on Wed Apr 02 09:43:28 GMT 2025
PRIMARY
CAS
54048-10-1
Created by admin on Wed Apr 02 09:43:28 GMT 2025 , Edited by admin on Wed Apr 02 09:43:28 GMT 2025
PRIMARY
SMS_ID
100000082090
Created by admin on Wed Apr 02 09:43:28 GMT 2025 , Edited by admin on Wed Apr 02 09:43:28 GMT 2025
PRIMARY
EPA CompTox
DTXSID9046782
Created by admin on Wed Apr 02 09:43:28 GMT 2025 , Edited by admin on Wed Apr 02 09:43:28 GMT 2025
PRIMARY
WIKIPEDIA
ETONOGESTREL
Created by admin on Wed Apr 02 09:43:28 GMT 2025 , Edited by admin on Wed Apr 02 09:43:28 GMT 2025
PRIMARY
PUBCHEM
6917715
Created by admin on Wed Apr 02 09:43:28 GMT 2025 , Edited by admin on Wed Apr 02 09:43:28 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> METABOLITE ACTIVE
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
PARENT -> IMPURITY
Related Record Type Details
ACTIVE MOIETY